MERSANA THERAPEUTICS INC (MRSN)
US59045L1061 - Common Stock
Notable Thursday Option Activity: PODD, BGS, MRSN
MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024
MRSN stock results show that Mersana Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...
Commit To Purchase Mersana Therapeutics At $3, Earn 25.5% Annualized Using Options
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in...
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
Tuesday Sector Laggards: Education & Training Services, Drugs
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.
Mersana Therapeutics announces business updates, expected 2024 milestones (NASDAQ:MRSN)
Mersana Therapeutics announces progress in Phase 1 clinical trials for XMT-1660 and XMT-2056, expects expansion in 2024, and plans to present at J.P.
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in...
Commit To Buy Mersana Therapeutics At $1, Earn 30% Using Options
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...
AbbVie-ImmunoGen M&A deal lifts ADC-focused biotechs
AbbVie's (ABBV) $10.1B acquisition of Immunogen (IMGN) boosts shares of smaller biotech's focused on antibody-drug conjugate (ADCs). Read more here.
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
Mersana stock jumps 7% as FDA lifts clinical hold on cancer drug (MRSN)
Mersana (MRSN) stock jumped on news that the FDA has lifted a clinical hold on its Phase 1 study for its anti-tumor drug candidate XMT-2056. Read more here.
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
Commit To Purchase Mersana Therapeutics At $1, Earn 37.1% Annualized Using Options
Mersana Therapeutics appoints Martin Huber as CEO (NASDAQ:MRSN)
Mersana Therapeutics (MRSN) announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the appointment of Martin Huber, M.D., current member of...
Mersana Therapeutics Announces Changes in Leadership
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. ("Mersana" or the "Company") (NASDAQ: MRSN). Such...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...